Acute myeloid leukaemia (AML) is the second most common leukaemia, accounting for 32% of all leukaemia in diagnosed in adults. AML is an aggressive malignancy of the bone marrow, as is characterized by uncontrolled proliferation of undifferentiated myeloid lineage cells and dismal survival rates, particularly among older patients. AML presents a significant clinical burden to the NHS because the intensive chemotherapy regimens necessary to bring the disease under control often result in hospitalisation due to side effects. There is therefore distinct clinical need of new therapies that will more specifically target the tumour with minimal toxicity.

  • Afghanistan
  • Albania
  • Antarctica
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Antigua and Barbuda
  • Azerbaijan
  • Argentina
  • Australia
  • Austria
  • Bahamas
  • Bahrain
  • Bangladesh
  • Armenia
  • Barbados
  • Belgium
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • Belize
  • British Indian Ocean Territory
  • Solomon Islands
  • Virgin Islands, British
  • Brunei Darussalam
  • Bulgaria
  • Myanmar
  • Burundi
  • Belarus
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Cayman Islands
  • Central African Republic
  • Sri Lanka
  • Chad
  • Chile
  • China
  • Taiwan
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Mayotte
  • Congo
  • Congo
  • Cook Islands
  • Costa Rica
  • Croatia
  • Cuba
  • Cyprus
  • Czech Republic
  • Benin
  • Denmark
  • Dominica
  • Dominican Republic
  • Ecuador
  • El Salvador
  • Equatorial Guinea
  • Ethiopia
  • Eritrea
  • Estonia
  • Faroe Islands
  • Falkland Islands (Malvinas)
  • South Georgia and the South Sandwich Islands
  • Fiji
  • Finland
  • Eland Islands
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Djibouti
  • Gabon
  • Georgia
  • Gambia
  • Palestine
  • Germany
  • Ghana
  • Gibraltar
  • Kiribati
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guinea
  • Guyana
  • Haiti
  • Heard Island and McDonald Islands
  • Vatican
  • Honduras
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Israel
  • Italy
  • Cote d'Ivoire
  • Jamaica
  • Japan
  • Kazakhstan
  • Jordan
  • Kenya
  • North Korea
  • South Korea
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Lebanon
  • Lesotho
  • Latvia
  • Liberia
  • Libya
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macao
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Martinique
  • Mauritania
  • Mauritius
  • Mexico
  • Midway Islands
  • Monaco
  • Mongolia
  • Moldova
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Oman
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Curacao
  • Aruba
  • Sint-Maarten
  • Bonaire, Sint-Estatius and Saba
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Norway
  • Northern Mariana Islands
  • United States Minor Outlying Islands
  • Micronesia
  • Marshall Islands
  • Palau
  • Pakistan
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn
  • Poland
  • Portugal
  • Guinea-Bissau
  • Timor-Leste
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russian Federation
  • Rwanda
  • Saint Barthelemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Anguilla
  • Saint Lucia
  • St. Maarten
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Slovakia
  • Vietnam
  • Slovenia
  • Somalia
  • South Africa
  • Zimbabwe
  • Spain
  • Southern Sudan
  • Sudan
  • Western Sahara
  • Suriname
  • Svalbard and Jan Mayen Islands
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • Tajikistan
  • Thailand
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • United Arab Emirates
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • North Macedonia
  • Egypt
  • United Kingdom
  • Guernsey
  • Jersey
  • Isle of Man
  • Tanzania, United Republic of
  • United States
  • Virgin Islands, U.S.
  • Burkina Faso
  • Uruguay
  • Uzbekistan
  • Venezuela
  • Wallis and Futuna
  • Samoa
  • Yemen
  • Zambia
  • South Ossetia
  • Kosovo
  • Vanuatu
  • Aland Islands
  • French Southern and Antarctic Lands
  • Life Sciences, Medicine & Health

Funded by the MRC for 3.5yrs, including a minimum of 3 months working within the industry partner. Funding will cover UK tuition fees and an enhanced stipend (around £17,785) only. We aim to support the most outstanding applicants from outside the UK. We are able to offer a limited number of bursaries that will enable full studentships to be awarded to international applicants. These full studentships will only be awarded to exceptional quality candidates, due to the competitive nature of this scheme.

Open to students worldwide

Universities: